These Analysts Revise Their Forecasts On Amgen After Q3 Results

Amgen Inc AMGN reported mixed third-quarter financial results.

Amgen reported quarterly sales of $6.90 billion, slightly missing the consensus of $6.94 billion. Adjusted EPS increased 6% to $4.96, driven by increased revenues, beating the consensus of $4.66.

Amgen said it expects FY23 adjusted EPS of $18.20-$18.80 versus prior guidance of $17.80-$18.80 and consensus of $18.26. The company sees FY23 revenues of $28 billion-$28.4 billion versus prior guidance of $26.6 billion-$27.4 billion and consensus of $27.54 billion.

Amgen shares gained 1.1% to trade at $258.52 on Wednesday.

These analysts made changes to their price targets on Amgen following earnings announcement.

  • Morgan Stanley slashed the price target on Amgen from $300 to $291. Morgan Stanley analyst Terence Flynn maintained an Equal-Weight rating.
  • RBC Capital increased the price target on Amgen from $253 to $256. RBC Capital analyst Gregory Renza maintained a Sector Perform rating.

Also Check This Out: Top 3 Consumer Stocks That Could Sink Your Portfolio In Q4

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidancePrice TargetMarketsAnalyst RatingsTrading IdeasPT Changes
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!